A reduced fixed dose of Tocilizumab 200 mg compared to 400 mg in patients with severe COVID-19 disease
Introduction. The deregulated excessive pro-inflammatory cytokine secretion have a detrimental impact on the evolution of COVID-19, aggregating the tissue impairment, organ failure, and increasing the risk for death. Several studies have demonstrated the beneficial effect of Tocilizumab (TCZ) in re...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Asociatia de Biosiguranta si Biosecuritate
2023-09-01
|
| シリーズ: | One Health & Risk Management |
| 主題: | |
| オンライン･アクセス: | https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/374 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|